Home

Convener, collaborator, catalyst in the fight against cancer.

At Project Data Sphere®, we believe in breaking down barriers to cancer clinical trial data sharing — barriers that historically have kept valuable trial data from ultimately benefitting the patients who so selflessly participate in them. By aggregating trial data from biopharmaceutical companies, academic medical centers, and government organizations and making it freely available on our open-access platform, we have established ourselves as a premier resource for the global oncology research community. Our deep relationships with renowned oncology experts allow us to convene research collaborations that leverage the power of pooled clinical trial data and which ultimately position PDS to be a catalyst for the discovery of urgently needed new treatments while helping to make cancer trials faster, more effective, and less expensive.

Data Providers

research-photo.jpg

External Control Arm

Conducting late-stage cancer trials without the need for a comparator arm could reduce patient enrollment time, cut costs, and preserve patient availability for other trials. Project Data Sphere's External Control Arm program is focused on making this a reality for cancer trials.

Images and Algorithms

Manually quantifying the size of solid tumors is both slow and subject to inter-reader variability. The Images and Algorithms program was created to accelerate these measurements and reduce inter-reader variability by developing a machine-learning algorithm to augment independent radiologist readings.

Rare Tumor Registries

Project Data Sphere’s MCC Tumor Registry is a prototype for a reliable source of publicly accessible information on rare diseases. Aggregating prospective patient-level data from multiple clinical sites, the registry offers an important source of information for natural history studies and, potentially, proof-of-concept for using real-world evidence in the drug-approval process.

Immune-Related Adverse Events

Project Data Sphere is driving solutions that remove barriers to data sharing in order to improve patient outcomes and expand cancer treatment options. The Immune-Related Adverse Events research program supports initiatives dedicated to improving the safety and efficacy of powerful immunotherapy treatments and decreasing the impact of associated adverse events.

Keep PDS 'Evergreen'

Since its launch in 2014, more than 2,600 researchers have accessed de-identified, patient-level data on the Project Data Sphere® platform. That's powerful.

But the true power of the platform comes from an ever-increasing volume of clinical trial data. By providing datasets, you help keep the platform "evergreen" for research, enabling investigators to continue to make groundbreaking discoveries for the benefit of cancer patients.

Provide Data

Latest News

Symposium IX - Rare Tumor Registries

October 7, 2020

Join us for FDA-PDS Symposium IX Rare Cancer Registries. This virtual event will be held October 7, 2020, from noon to 3:00 p.m. (EDT). Registration is now open.

More details and full agenda

Home

More about the Project Data Sphere platform

Data Providers

Sponsored Research